From @jamapediatrics.com 💉🦠
Infants receiving #nirsevimab experience a significantly lower risk for hospitalization for #RSV-related lower respiratory tract infections during their first year of life. #IDSky
@infectiousdisease.bsky.social
@infectiousdisease.bsky.socialFrom @jamapediatrics.com 💉🦠
Infants receiving #nirsevimab experience a significantly lower risk for hospitalization for #RSV-related lower respiratory tract infections during their first year of life. #IDSky
@springermedicine.com#MedCase - Primary resistance to #nirsevimab has rarely been reported since its implementation.
The detection of a nirsevimab-resistant RSV-B strain in a monoclonal antibody-naïve adult raises concerns that such variants may be in circulation.
@castltrastondrs.medsky.network#Medsky🧪 #immunosky #pedsky #pharmsky #publichealth @JAMA The findings of this study suggest that #nirsevimab is highly effective in preventing severe #RSV disease that requires hospital-based care and can substantially reduce the burden of severe RSV disease.
@bionewscentral.com#Immunization with #nirsevimab, a long-acting #antibody, protected #infants against #RSV and sharply reduced #hospitalizations and #ICU admissions.
#RSVprevention
@vaccinologist.bsky.socialReal-world data from @ucalgary.bsky.social on #nirsevimab #Beyfortus: 79% effectiveness vs. #RSV hospitalization, 97% vs. ICU admission in infants. Severe RSV seen in otherwise healthy babies, supporting broad prevention rather than risk-based targeting alone. www.linkedin.com/posts/drmelv...
@jamanetworkopen.com📈 Among infants who were tested for respiratory syncytial virus (#RSV) in 2 Canadian provinces, receipt of #Nirsevimab was associated with lower risk of RSV-related emergency department visits, hospitalization, and intensive care unit admission.
